Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1

Table 2 Sustained virological response 12 rates according to clinical and demographical factors

Parameters	n	SVR 12 (%)	P value
Sex			0.6272
Male	103	100.0
Female	143	98.6
Age (yr)			0.8287
< 75	167	99.4
≥ 75	79	98.7
HCV RNA (log10IU/mL)			0.7076
< 6.0	93	100.0
≥ 6.0	153	98.7
Liver fibrosis			0.8811
No cirrhosis	195	99.5
Cirrhosis	51	98.0
Fib-4 index			0.4634
< 3.25	125	100.0
≥ 3.25	121	98.3
Prior treatment			0.8931
Treatment naïve	194	99.0
Treatment experienced	52	100.0
Previous HCC treatment			0.2868
No	230	99.6
Yes	16	93.8
NS5A RAVs			0.5471
None	48	97.9
Y93	22	100.0
L31	6	83.3
Y93/L31	5	100.0

RAVs: Resistance-associated variants; HCC: Hepatocellular carcinoma; SVR: Sustained virological response.